Phibro Animal Health (NASDAQ:PAHC) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Tuesday.

PAHC has been the subject of a number of other reports. Zacks Investment Research cut shares of Phibro Animal Health from a “hold” rating to a “sell” rating in a research note on Wednesday, August 29th. Morgan Stanley boosted their price objective on shares of Phibro Animal Health from $36.00 to $46.00 and gave the stock an “underweight” rating in a research note on Wednesday, August 29th. Finally, Barclays boosted their price objective on shares of Phibro Animal Health from $31.00 to $33.00 and gave the stock an “underweight” rating in a research note on Thursday, July 5th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $43.20.

NASDAQ PAHC opened at $43.35 on Tuesday. The company has a quick ratio of 1.66, a current ratio of 2.90 and a debt-to-equity ratio of 1.62. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of 24.91, a price-to-earnings-growth ratio of 2.59 and a beta of 0.89. Phibro Animal Health has a 12-month low of $32.05 and a 12-month high of $54.62.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Monday, August 27th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.04. The firm had revenue of $211.80 million during the quarter, compared to analysts’ expectations of $209.27 million. Phibro Animal Health had a net margin of 7.90% and a return on equity of 39.81%. The company’s revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.39 earnings per share. analysts anticipate that Phibro Animal Health will post 1.8 EPS for the current fiscal year.

In other news, VP Daniel M. Bendheim sold 2,500 shares of the business’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $44.30, for a total value of $110,750.00. Following the completion of the sale, the vice president now directly owns 2,500 shares in the company, valued at $110,750. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jack Bendheim sold 30,000 shares of the business’s stock in a transaction on Thursday, June 21st. The stock was sold at an average price of $47.56, for a total transaction of $1,426,800.00. The disclosure for this sale can be found here. Insiders sold 383,960 shares of company stock valued at $18,474,427 over the last 90 days. 51.88% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. Alps Advisors Inc. acquired a new position in Phibro Animal Health during the 2nd quarter valued at $431,000. Prudential Financial Inc. raised its stake in Phibro Animal Health by 37.7% during the 1st quarter. Prudential Financial Inc. now owns 189,070 shares of the company’s stock valued at $7,506,000 after purchasing an additional 51,800 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Phibro Animal Health by 1.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 482,718 shares of the company’s stock valued at $19,164,000 after purchasing an additional 4,674 shares during the last quarter. Royal Bank of Canada raised its stake in Phibro Animal Health by 2,104.6% during the 1st quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock valued at $151,000 after purchasing an additional 3,641 shares during the last quarter. Finally, Stevens First Principles Investment Advisors acquired a new position in Phibro Animal Health during the 2nd quarter valued at $569,000. Institutional investors and hedge funds own 50.45% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.

See Also: Stock Symbols Definition, Examples, Lookup

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.